ConductScience.org, home

Paper646348

Amphotericin B pharmacokinetics in humans.

Atkinson AJ and 1 other. Antimicrob Agents Chemother, 1978. Cited by 215 papers, by iCite.

Cite this record

ConductScience Library. Amphotericin B pharmacokinetics in humans. Papers, record 646348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/646348

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Amphotericin B pharmacokinetics in humans.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1978
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
215
iCite
Relative citation ratio, by iCite
10.5
iCite
Revised in PubMed
2022-04-10
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Atkinson AJ JrA J
2Bennett JEJ E

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Amphotericin BMajor topic
Aged
Biological Assay
Humans
Kinetics
Male
Middle Aged
Models, Biological

Source PubMed

Download CSV of topics

References11

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
2829788Plasma and tissue protein binding of drugs in pharmacokinetics.Drug Metab Rev1976https://conductscience.org/library/papers/829788PubMed
35394441A pharmacologic guide to the clinical use of amphotericin B.J Infect Dis1969https://conductscience.org/library/papers/5394441PubMed
44586143Amphotericin B therapy in an anephric patient.Antimicrob Agents Chemother1973https://conductscience.org/library/papers/4586143PubMed
54823813Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man.Ann Intern Med1974https://conductscience.org/library/papers/4823813PubMed
64423599Clearance and biologic half-life as indices of intrinsic hepatic metabolism.J Pharmacol Exp Ther1974https://conductscience.org/library/papers/4423599PubMed
74593887Chemotherapy of systemic mycoses (first of two parts).N Engl J Med1974https://conductscience.org/library/papers/4593887PubMed
84987171The effect of diphenylhydantoin on thyroxine metabolism in man.J Clin Invest1970https://conductscience.org/library/papers/4987171PubMed
95110737Increased permeability of human erythrocytes induced by amphotericin B.J Infect Dis1971https://conductscience.org/library/papers/5110737PubMed
105456013Amphotericin B serum concentrations during therapy.Appl Microbiol1970https://conductscience.org/library/papers/5456013PubMed
115819291Pharmacokinetics of intrathecally administered amphotericin B.Am Rev Respir Dis1969https://conductscience.org/library/papers/5819291PubMed
125672740Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy.Am J Med1968https://conductscience.org/library/papers/5672740PubMed

Download CSV of references

Cited by61

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 215 citations.

PMIDTitleJournalYearIn PapersSource
42984876Pharmacokinetic and pharmacodynamic strategies to optimize antifungal therapy, prevent resistance and minimize treatment failure.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42984876PubMed
40381011Advancing fungal keratitis treatment: transitioning from conventional amphotericin B therapy to nanocarrier-based delivery systems.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/40381011PubMed
35064965Berkeley Madonna Version 10-A simulation package for solving mathematical models.CPT Pharmacometrics Syst Pharmacol2022https://conductscience.org/library/papers/35064965PubMed
34065929Macrolides: From Toxins to Therapeutics.Toxins (Basel)2021https://conductscience.org/library/papers/34065929PubMed
33523419Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.Infect Dis Ther2021https://conductscience.org/library/papers/33523419PubMed
31551999
Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated With Amphotericin B Plus Flucytosine Alone or in Combination With Fluconazole.
Front Microbiol2019https://conductscience.org/library/papers/31551999PubMed
30056571Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.J Mater Sci Mater Med2018https://conductscience.org/library/papers/30056571PubMed
28702763Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Infection2017https://conductscience.org/library/papers/28702763PubMed
28480108
Fungal brain abscess caused by "Black Mold" (Cladophialophora bantiana) - A case report of successful treatment with an emphasis on how fungal brain abscess may be different from bacterial brain abscess.
Surg Neurol Int2017https://conductscience.org/library/papers/28480108PubMed
27821250Antifungal pharmacodynamics: Latin America's perspective.Braz J Infect Dis2017https://conductscience.org/library/papers/27821250PubMed
26349818Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/26349818PubMed
24872147Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.Drugs2014https://conductscience.org/library/papers/24872147PubMed
24595533Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Clin Pharmacokinet2014https://conductscience.org/library/papers/24595533PubMed
24456292Novel chemotherapeutic strategies in the management of primary amoebic meningoencephalitis due to Naegleria fowleri.CNS Neurosci Ther2014https://conductscience.org/library/papers/24456292PubMed
21854638In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines.Lipids Health Dis2011https://conductscience.org/library/papers/21854638PubMed
21431453Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.AAPS J2011https://conductscience.org/library/papers/21431453PubMed
20540940Flow cytometric screening for anti-leishmanials in a human macrophage cell line.Exp Parasitol2010https://conductscience.org/library/papers/20540940PubMed
19741525Pediatric antifungal agents.Curr Opin Infect Dis2009https://conductscience.org/library/papers/19741525PubMed
15101785Antifungals in systemic neonatal candidiasis.Drugs2004https://conductscience.org/library/papers/15101785PubMed
11850268Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/11850268PubMed

See all 61 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/646348

GET https://conductscience.org/api/papers/v1/646348/cited_by?page=2